What is 4D Molecular Therapeutics Inc Quarterly Revenue?

4D Molecular Therapeutics Inc Quarterly Revenue 4D Molecular Therapeutics Inc Jun-2026 Quarterly Revenue is $4 Million which is growth of 25106.7% YoY.

What is 4D Molecular Therapeutics Inc Quarterly Net Profit?

4D Molecular Therapeutics Inc Quarterly Net Profit 4D Molecular Therapeutics Inc Jun-2026 Quarterly Net Profit is $-73 Million which is growth of -33.4% YoY.

What is 4D Molecular Therapeutics Inc Annual Revenue?

4D Molecular Therapeutics Inc Annual Revenue 4D Molecular Therapeutics Inc Dec-2025 Annual Revenue is $85 Million which is growth of 230194.6% YoY.

What is 4D Molecular Therapeutics Inc Annual Net Profit?

4D Molecular Therapeutics Inc Annual Net Profit 4D Molecular Therapeutics Inc Dec-2025 Annual Net Profit is $-140 Million which is growth of 12.9% YoY.

What is 4D Molecular Therapeutics Inc Total Shareholders Fund?

4D Molecular Therapeutics Inc Total Shareholders Fund 4D Molecular Therapeutics Inc Dec-2025 Total Shareholders Fund is $506 Million which is growth of -1.0% YoY.

What is 4D Molecular Therapeutics Inc Total Assets?

4D Molecular Therapeutics Inc Total Assets 4D Molecular Therapeutics Inc Dec-2025 Total Assets is $567 Million which is growth of 1.1% YoY.

What is 4D Molecular Therapeutics Inc Book Value Per Share?

4D Molecular Therapeutics Inc Book Value Per Share 4D Molecular Therapeutics Inc Book Value Per Share is $7 which is growth of -18.1% YoY.

What is 4D Molecular Therapeutics Inc ROE?

4D Molecular Therapeutics Inc ROE 4D Molecular Therapeutics Inc ROE is 0% which is growth of 0% YoY.

What is 4D Molecular Therapeutics Inc Cash From Operating Activity?

4D Molecular Therapeutics Inc Cash From Operating Activity 4D Molecular Therapeutics Inc Dec-2025 Cash From Operating Activity is $-109 Million which is growth of 18.9% YoY.

What is 4D Molecular Therapeutics Inc Net Cash Flow?

4D Molecular Therapeutics Inc Net Cash Flow 4D Molecular Therapeutics Inc Dec-2025 Net Cash Flow is $-89 Million which is growth of 10.7% YoY.

4D Molecular Therapeutics Inc

XNAS: FDMT

Momentum Trap

Download real time

-0.75(-5.49%)

85.63% Gain from 52W Low

2.1M

XNAS Volume

High volume+loss today

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

4D Molecular Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for 4D Molecular Therapeutics Inc share price target, revenues, EPS, net income and more

4D Molecular Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue 4D Molecular Therapeutics Inc Jun-2026 Quarterly Revenue is $4 Million which is growth of 25106.7% YoY.
NEGATIVE
Quarterly Net Profit 4D Molecular Therapeutics Inc Jun-2026 Quarterly Net Profit is $-73 Million which is growth of -33.4% YoY.

4D Molecular Therapeutics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	3.8	3.1	85.1	0.1	0	0				0	-0	20.2	0.2
CostOfRevenue_Q Cost Of Rev.	-	-	-	-	-	-	-	-	-	-	-	-	-
GrossProfit_Q Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
OEXPNS_Q Operating Exp. ⌄	80.8	76.7	70.4	61.3	59.5	53.6	56.1	51.1	42.5	38.2	36.6	34.2	32.4
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	12.5	11.7	12.8	11.8	11.5	12.9	13	12.7	10.6	10.3	10.6	9.1	8.8
ResearchAndDevlopmentExpenses_Q RnD Exp.	68.3	65	57.6	49.4	48	40.7	43.1	38.5	31.9	27.9	26	25.1	23.6
OP_Q Operating Profit	-77	-73.6	14.7	-61.2	-59.5	-53.6	-56.1	-51.1	-42.5	-38.1	-36.7	-14	-32.1
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	4.3	4.9	4.7	4.3	4.9	5.6	6.5	7.3	7.6	5.8	4.4	3.9	2.5
Others_Q Other Interest Earned	4.3	4.9	4.7	4.3	4.9	5.6	6.5	7.3	7.6	5.7	4.4	3.9	2.5
IntExpNonOperating_Q Interest Exp. Non Operating	-	-	-	-	-	-	-	-	-	-	-	-	-
PBT_Q Profit Before Tax	-72.9	-68.8	19.4	-56.9	-54.7	-48	-49.7	-43.8	-35	-32.4	-32.3	-10.3	-29.6
TAX_Q Tax	-	-	-	-	-	-	-	-	-	-	-	-	-
NICommonStockholders_Q Net Income Common Stockholders ⌄	-72.9	-68.8	19.4	-56.9	-54.7	-48	-49.7	-43.8	-35	-32.4	-32.3	-10.3	-29.6
NP_Q Net Profit	-72.9	-68.8	19.4	-56.9	-54.7	-48	-49.7	-43.8	-35	-32.4	-32.3	-10.3	-29.6
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-72.9	-68.8	19.4	-56.9	-54.7	-48	-49.7	-43.8	-35	-32.4	-32.3	-10.3	-29.6
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-72.9	-68.8	19.4	-56.9	-54.7	-48	-49.7	-43.8	-35	-32.4	-32.3	-10.3	-29.6
EPS_Q Basic EPS	-1	-1	0.4	-1	-1	-0.9	-0.9	-0.8	-0.6	-0.7	-0.8	-0.2	-0.8
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-1	-1	0.4	-1	-1	-0.9	-0.9	-0.8	-0.6	-0.7	-0.8	-0.2	-0.8
SHARE_Q Number Of Shares End	70.3	68.1	63.9	56.1	55.9	55.7	55.6	55.6	55.3	49.3	42.9	42.3	38.3
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-72.9	-68.8	19.4	-56.9	-54.7	-48	-49.7	-43.8	-35	-32.4	-32.3	-10.3	-29.6
NormalizedIncome_Q Normalized Income	-72.9	-68.8	19.4	-56.9	-54.7	-48	-49.7	-43.8	-35	-32.4	-32.3	-10.3	-29.6
InterestIncome_Q Interest Income	4.3	4.9	4.7	4.3	4.9	5.6	6.5	7.3	7.6	5.8	4.4	3.9	2.5
INT_Q Interest	-	-	-	-	-	-	-	-	-	-	-	-	-
NetInterestIncome_Q Net Interest Income	4.3	4.9	4.7	4.3	4.9	5.6	6.5	7.3	7.6	5.8	4.4	3.9	2.5
EBIT_Q EBIT	-77	-73.6	14.7	-61.2	-59.5	-53.6	-56.1	-51.1	-42.5	-38.1	-36.7	-14	-32.1
EBITDA_Q EBITDA	-74.9	-71.6	16.7	-59.2	-57.6	-51.9	-54.3	-49.4	-40.8	-36.5	-35.1	-12.6	-30.7
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	-	-	-	-	-	-	-	-	-	-	-	-	-
ReconciledDepreciation_Q Reconciled Depr.	2.1	2.1	2	2	1.9	1.8	1.8	1.7	1.6	1.6	1.5	1.4	1.4
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-72.9	-68.8	19.4	-56.9	-54.7	-48	-49.7	-43.8	-35	-32.4	-32.3	-10.3	-29.6
NormalizedEBITDA_Q Normalized EBITDA	-74.9	-71.6	16.7	-59.2	-57.6	-51.9	-54.3	-49.4	-40.8	-36.5	-35.1	-12.6	-30.7

*All financials are in USD Million and price data in USD

Add metric to table

Search...

4D Molecular Therapeutics Inc competitor comparison and performance snapshot within industry

4D Molecular Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue 4D Molecular Therapeutics Inc Dec-2025 Annual Revenue is $85 Million which is growth of 230194.6% YoY.
POSITIVE
Annual Net Profit 4D Molecular Therapeutics Inc Dec-2025 Annual Net Profit is $-140 Million which is growth of 12.9% YoY.

4D Molecular Therapeutics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17
SR_A Total Rev. Ann. ⌄	201.8%	44.3%		85.2	0	20.7	3.1	18	13.6	7	14.1	5.8
TotalOperatingRevenues_A Operating Rev. Ann.	201.8%	44.3%	92	85.2	0	20.7	3.1	18	13.6	7	14.1	5.8
CostOfRevenue_A Cost Of Rev. Ann.	-	-		-	-	-	-	-	-	-	-	-
GrossProfit_A Gross Profit Ann.	-	-		-	-	-	-	-	-	-	-	-
OEXPNS_A Operating Exp. Ann.	29.3%	28.3%	289.1	244.8	187.9	133.6	113.2	89.4	70.3	52.6	24.5	17.1
OP_A Operating Profit Ann.	-	-	-197.1	-159.6	-187.8	-112.9	-110	-71.3	-56.7	-45.6	-10.4	-11.3
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	95.7%	149.9%	18.2	19.5	27.1	12.2	2.6	0.1	0.2	1.5	0.9	0.1
Others_A Other Interest Earned Ann.	95.7%	149.9%	18.2	19.5	27.1	12.2	2.6	0.1	0.2	1.5	0.9	0.1
IntExpNonOperating_A Interest Exp. Non Operating Ann.	-	-		-	-	-	-	-	-	-	-	-
OtherExpenses_A Other Exp. Ann.	-	-		-0	-0.1	-0.2	-0	-0.1	-0.2	-5.2		-0
PBT_A PBT Ann.	-	-	-179.2	-140.1	-160.9	-100.8	-107.5	-71.3	-56.7	-49.3	-9.6	-11.2
TAX_A Tax Ann.	-	-		-	-	-	-	-	-	-	-	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	-	-179.2	-140.1	-160.9	-100.8	-107.5	-71.3	-56.7	-49.3	-9.6	-11.2
NP_A Net Profit Ann.	-	-	-179.2	-140.1	-160.9	-100.8	-107.5	-71.3	-56.7	-49.3	-9.6	-11.2
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	-	-179.2	-140.1	-160.9	-100.8	-107.5	-71.3	-56.7	-49.3	-9.6	-11.2
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	-	-179.2	-140.1	-160.9	-100.8	-107.5	-71.3	-56.7	-49.3	-9.6	-11.2
EPS_A EPS Ann.	-	-		-2.4	-3	-2.6	-3.3	-2.6	-8.8	-3.9	-0.6	-0.8
DilutedEPS_A Diluted EPS Ann.	-	-		-2.4	-3	-2.6	-3.3	-2.6	-8.8	-3.9	-0.6	-0.8
SHARE_Q Number Of Shares End	25.3%	19.1%		63.9	55.6	42.9	32.5	30.5	26.7	14.8	21.6	-
TotalExpenses_A Total Exp. Ann.	29.3%	28.3%		244.8	187.9	133.6	113.2	89.4	70.3	52.6	24.5	17.1
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	-	-179.2	-140.1	-160.9	-100.8	-107.5	-71.3	-56.7	-49.3	-9.6	-11.2
NormalizedIncome_A Normalized Income Ann.	-	-	-179.2	-140.1	-160.9	-100.8	-107.5	-71.3	-56.7	-44.2	-9.6	-11.2
InterestIncome_A Interest Income Ann.	95.7%	149.9%	18.2	19.5	27.1	12.2	2.6	0.1	0.2	1.5	0.9	0.1
INT_A Interest Ann.	-	-		-	-	-	-	-	-	-	-	-
EBITDA_A EBITDA Ann.	-	-	-189	-151.9	-181.1	-107.1	-106.2	-68.3	-55.2	-44.6	-9.7	-10.7
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	-	-		-	-	-	-	-	-	-	-	-
ReconciledDepreciation_A Reconciled Depr. Ann.	24.9%	40.3%	8.1	7.6	6.7	5.8	3.9	3	1.4	1	0.7	0.6
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-179.2	-140.1	-160.9	-100.8	-107.5	-71.3	-56.7	-49.3	-9.6	-11.2
NormalizedEBITDA_A Normalized EBITDA Ann.	-	-	-189	-151.9	-181.1	-107.1	-106.2	-68.3	-55.2	-39.5	-9.7	-10.7

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

2Y CAGR

102.9%

3Y CAGR

201.8%

5Y CAGR

44.3%

7Y CAGR

29.3%

Total Revenue Annual growth is higher than historical averages.

Operating Exp. Ann.

1Y CHG

30.3%

2Y CAGR

35.4%

3Y CAGR

29.3%

5Y CAGR

28.3%

7Y CAGR

38.9%

Operating Expenses Annual Cr growth is stable compared to historical averages.

4D Molecular Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Total Shareholders Fund 4D Molecular Therapeutics Inc Dec-2025 Total Shareholders Fund is $506 Million which is growth of -1.0% YoY.
POSITIVE
Total Assets 4D Molecular Therapeutics Inc Dec-2025 Total Assets is $567 Million which is growth of 1.1% YoY.

4D Molecular Therapeutics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17
TA_A Total Assets Ann. ⌄	29.3%	14.5%	566.7	560.4	339.9	261.9	353.5	288.3	58.2	97	27.3
CA_A Total Current Assets Ann.	23.3%	7.9%	413.1	434.9	296.6	220.5	256.3	282.7	52.5	94.1	24.5
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	23.5%	7.8%	402.7	424.9	288.2	213.6	247.8	276.7	49.7	91.8	23.9
Receivables_A Change In Account Receivables Ann.	-	-	-	-	-		0.1	1.5	1	1.1	0.3
Inventories_A Inventories Ann.	-	-	-	-	-	-	-	-	-	-	-
OtherCurrentAssets_A Other Current Assets Ann.	14.5%	-	10.5	10.1	8.4	7	-	-	-	-	-
TotalNonCurrentAssets_A Total Non Current Assets Ann.	54.9%	93.2%	153.6	125.5	43.3	41.3	97.2	5.7	5.7	2.9	2.8
NetPPE_A Net PPE Ann.	-2.3%	45.3%	33	40.6	31.7	35.4	29	5.1	5.1	2.5	2.7
InvestmentsAndAdvances_A Investments & Advances Ann.	183.3%	-	111.4	80.6	11	4.9	67.7	-	-	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	103%	72.6%	9.2	4.3	0.7	1.1	0.6	0.6	0.7	0.4	0.1
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	26.1%	13.9%	61.1	49.8	32.1	30.5	34.4	31.9	131.2	124.6	46.9
CL_A Total Current Liabilities Ann.	41%	21.4%	44	29.2	19	15.7	16.3	16.7	13	8.1	5.9
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	46%	30.1%	38	23.3	15.5	12.2	12.5	10.2	7.1	3.2	1.5
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	27.5%	-	5.6	5.6	3.2	2.7	1.2	-	-	-	-
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-23.7%	-42.9%	0.4	0.3	0.3	0.9	2.6	6.6	5.9	4.9	-
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	4.9%	2.4%	17.1	20.6	13.1	14.8	18	15.2	118.3	116.5	41
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	5.4%	-	15.8	19	11.5	13.5	15.2	-	-	-	-
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	0.1	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	29.8%	14.5%	505.7	510.6	307.8	231.3	319.1	256.4	-73	-27.6	-19.6
EQCAP_A Equity Share Capital Ann.	29.8%	14.5%	505.7	510.6	307.8	231.3	319.1	256.4	-73	-27.6	-19.6
CapitalStock_A Capital Stock Ann.	-	-	0	0
RetainedEarnings_A Retained Earnings Ann.	-	-	-716.3	-576.2	-415.3	-314.5	-207	-135.7	-79	-30	-20.5
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	-	0.7	0.2	0	-1.2	-0.4	-	-	-	-
TotalCapitalization_A Total Capitalization Ann.	29.8%	14.5%	505.7	510.6	307.8	231.3	319.1	256.4	-73	-27.6	-19.6
TangibleAssets_A Tangible Assets Ann.	29.8%	14.5%	505.7	510.6	307.8	231.3	319.1	256.4	-73	-27.6	-19.6
WC_A Working Capital Ann.	21.7%	6.8%	369.2	405.8	277.6	204.8	239.9	265.9	39.6	86	18.6
InvestedCapital_A Invested Capital Ann.	29.8%	14.5%	505.7	510.6	307.8	231.3	319.1	256.4	-73	-27.6	-19.6
TangibleBookValue_A Tangible Book Value Ann.	29.8%	14.5%	505.7	510.6	307.8	231.3	319.1	256.4	-73	-27.6	-19.6
Borrowings_A Borrowings Ann.	10%	-	21.4	24.6	14.7	16.1	16.5	-	-	-	-
NetDebt_A Net Debt Ann.	-	-	-	-	-	-	-	-	-	-	-
ShareIssued_A Share Issued Ann.	20.9%	16.6%	57.6	45.8	43.1	32.6	32.2	26.7	21.6	21.6	21.6
SHARE_Q Number Of Shares End	25.3%	19.1%	63.9	55.6	42.9	32.5	30.5	26.7	14.8	21.6	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

1.1%

2Y CAGR

29.1%

3Y CAGR

29.3%

5Y CAGR

14.5%

7Y CAGR

28.7%

Total Assets Annual growth is lower than historical averages.

Total Current Liabilities Ann.

1Y CHG

50.7%

2Y CAGR

52.2%

3Y CAGR

41%

5Y CAGR

21.4%

7Y CAGR

27.3%

Total Current Liabilities Annual Cr growth is higher than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

-1%

2Y CAGR

28.2%

3Y CAGR

29.8%

5Y CAGR

14.5%

Total ShareHolders Funds Annual is falling faster than historical averages.

4D Molecular Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Book Value Per Share 4D Molecular Therapeutics Inc Book Value Per Share is $7 which is growth of -18.1% YoY.
NEUTRAL
ROE 4D Molecular Therapeutics Inc ROE is 0% which is growth of 0% YoY.

4D Molecular Therapeutics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17
ROA_A RoA Ann. %	-	-	-	-35.74%	-33.52%	-34.94%	-22.22%	-32.72%	-63.54%	-15.37%	-41.08%
ROE_A ROE Ann. %	-	-	-	-39.31%	-37.40%	-39.06%	-24.78%	-61.82%	-	-	-
ROIC_Q ROIC %	-	-	-	-10.1	-11	-11.1	-8.6	-12.6	-	-	-
OPMPCT_A OPM Ann. %	-	-	-187.24%	-507,678.38%	-544.65%	-3,516.52%	-395.46%	-416.28%	-653.12%	-73.60%	-194.68%
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	-	-	-	-	-	-	-	-
ASETTO_A Asset Turnover Ann. %	-	-	-		0.1	0	0.1	0.1	0.1	0.2	0.2
WCTO_A Working Capital Turnover Ann.	-	14.9%	0.2		0.1	0	0.1	0.1	0.2	0.2	0.3
QuickRatio_A Quick Ratio Ann.	-	-	-	14.6	15.2	13.6	15.2	16.6	3.9	11.5	4.1
CRATIO_A Current Ratio Ann.	-	-	-	14.9	15.7	14	15.7	16.9	4.1	11.7	4.2
IC_A Interest Coverage Ratio Ann.	-	-	-	-	-	-	-	-	-	-	-
LTDE_A LT Debt To Equity Ann.	-	-	-	0	0	0.1	0.1	-	-	-	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

4D Molecular Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Cash From Operating Activity 4D Molecular Therapeutics Inc Dec-2025 Cash From Operating Activity is $-109 Million which is growth of 18.9% YoY.
POSITIVE
Net Cash Flow 4D Molecular Therapeutics Inc Dec-2025 Net Cash Flow is $-89 Million which is growth of 10.7% YoY.

4D Molecular Therapeutics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17
CFO_A Cash from Operating Act. Ann. ⌄	-	-	-109.1	-134.6	-75.8	-86.7	-69.1	-50.9	-36.7	-16.3	8.2
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-140.1	-160.9	-100.8	-107.5	-71.3	-56.7	-49.3	-9.6	-11.2
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	24.9%	40.3%	7.6	6.7	5.8	3.9	3	1.4	1	0.7	0.6
DepreciationAndAmortization_A Depreciation And Amortization Ann.	24.9%	40.3%	7.6	6.7	5.8	3.9	3	1.4	1	0.7	0.6
DeferredTax_A Deferred Tax Ann.	-	-	-	-	-	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	-	-	-	-	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	8.8%	34.5%	22	26.1	19.7	17.1	13.8	5	3.5	1.4	0.3
OtherNonCashItems_A Other Non Cash Items Ann.	-	-	-	-	-	-	-	-	5.1	-	-
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	6.2	0.5	0.6	-1.3	-15.5	-0.7	0.3	-8.8	18.5
ChangeInReceivables_A Change In Receivables Ann.	-	-	-	-		0.1	1.4	-0.5	0.2	-0.8	-0.3
ChangeInInventory_A Change In Inventory Ann.	-	-	-	-	-	-	-	-	-	-	-
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	154.9%	51%	14.9	7.4	4.3	0.9	3	1.9	4.4	1.8	-0.2
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	-4.9	-3.6	-0.1	-0		0.1	-0.2	-0.3
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	-3.2	-1.7	-1.5	-0.3	-1	-	-	-	-
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-0.2	0.1	-0.7	-3.1	-14.7	0.3	-3.4	-8.6	19
CFI_A Cash from Investing Act. Ann. ⌄	-	-	-93	-302.4	115.7	-17.1	-172.7	-1	-3.2	-0.4	7.7
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-0.5	-3.8	-2.8	-11.5	-9.1	-1	-3.2	-0.4	-0.6
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-0.5	-3.8	-2.8	-11.5	-9.1	-1	-3.2	-0.4	-0.6
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-	-	-	-	-	-	-	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-	-	-	-	-	-	-	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-442.8	-467.7	-54.8	-153.3	-168.6	-	-	-	-
SaleOfInvestment_A Sale Of Investment Ann.	33.3%	-	350.4	169	173.3	147.8	5	-	-		8.2
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	-	-	-	-	-	-
CFA_A Cash from Financing Act. Ann. ⌄	231.6%	-16.5%	113	337.3	156.8	3.1	118.1	279	-2.2	84.6	0
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-	-	-	-	-	-	-	-	-	-
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	-	-11.7%	110.7	331.4	148.3		114.3	205.7	0.1	0.1	0
CommonStockIssuance_A Common Stock Issuance Ann.	-	-11.7%	110.7	331.4	148.3		114.3	205.7	0.1	0.1	0
CommonStockPayments_A Common Stock Payments Ann.	-	-	-	-	-	-	-	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-	-	-	-0.5	-	-	-2.3	-	-
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	4.7%	-26.3%	60.2	149.3	249.1	52.4	153	276.7	49.7	91.8	23.9
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	-	-89.1	-99.8	196.8	-100.7	-123.7	227.1	-42.1	67.9	15.9
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-0.8%	24.6%	149.3	249.1	52.4	153	276.7	49.7	91.8	23.9	7.9
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-	-
CapitalExpenditure_A Capex Ann.	-	-	-0.5	-3.8	-2.8	-11.5	-9.1	-1	-3.2	-0.4	-0.6
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	-	-16.8%	110.7	331.4	148.3		114.3	278.1	0.1	84.6	0
IssuanceOfDebt_A Issuance Of Debt Ann.	-	-	-	-	-	-	-	-	-	-	-
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-	-	-	-	-	-	-	-	-
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-	-	-	-	-	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	-	-	-109.6	-138.4	-78.6	-98.2	-78.2	-51.9	-39.9	-16.7	7.7

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Financing Act. Ann.

1Y CHG

-66.5%

2Y CAGR

-15.1%

3Y CAGR

231.6%

5Y CAGR

-16.5%

7Y CAGR

4.2%

Cash from Financing Annual Activity is falling faster than historical averages.

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

85.63% Gain from 52W Low

High volume+loss today

4D Molecular Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

4D Molecular Therapeutics Inc - Forecaster

Forecaster Analyst Estimates for 4D Molecular Therapeutics Inc share price target, revenues, EPS, net income and more

4D Molecular Therapeutics Inc - Earnings Report - Quarterly Results

4D Molecular Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue 4D Molecular Therapeutics Inc Jun-2026 Quarterly Revenue is $4 Million which is growth of 25106.7% YoY.

Quarterly Net Profit 4D Molecular Therapeutics Inc Jun-2026 Quarterly Net Profit is $-73 Million which is growth of -33.4% YoY.

4D Molecular Therapeutics Inc - Competitors/Peers

4D Molecular Therapeutics Inc competitor comparison and performance snapshot within industry

4D Molecular Therapeutics Inc - Earnings Report - Annual Results

4D Molecular Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue 4D Molecular Therapeutics Inc Dec-2025 Annual Revenue is $85 Million which is growth of 230194.6% YoY.

Annual Net Profit 4D Molecular Therapeutics Inc Dec-2025 Annual Net Profit is $-140 Million which is growth of 12.9% YoY.

4D Molecular Therapeutics Inc - Balance Sheet

4D Molecular Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund 4D Molecular Therapeutics Inc Dec-2025 Total Shareholders Fund is $506 Million which is growth of -1.0% YoY.

Total Assets 4D Molecular Therapeutics Inc Dec-2025 Total Assets is $567 Million which is growth of 1.1% YoY.

4D Molecular Therapeutics Inc - Ratios

4D Molecular Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share 4D Molecular Therapeutics Inc Book Value Per Share is $7 which is growth of -18.1% YoY.

ROE 4D Molecular Therapeutics Inc ROE is 0% which is growth of 0% YoY.

4D Molecular Therapeutics Inc - Cash Flow

4D Molecular Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity 4D Molecular Therapeutics Inc Dec-2025 Cash From Operating Activity is $-109 Million which is growth of 18.9% YoY.

Net Cash Flow 4D Molecular Therapeutics Inc Dec-2025 Net Cash Flow is $-89 Million which is growth of 10.7% YoY.